Imperagen Partnership Featured in Speciality Chemicals Magazine

In collaboration with Zanoprima Lifesciences and Enzymicals AG, we’ve advanced a next-generation biosynthetic route for producing SyNic™—a high-purity, sustainable form of (S)-nicotine developed specifically for smoking cessation therapies.

Leveraging our Digital Enzyme Evolution™ platform, we achieved a 10-fold increase in enzyme productivity in just two engineering cycles. This breakthrough holds significant promise for improving efficiency and reducing costs in our partners’ existing tonne-scale production process.

“For our patented synthetic route to be workable we needed an enzyme for the key step to be sufficiently selective and productive. The one identified by Enzymicals has been used to manufacture many tonnes of (S)-nicotine in a sustainable and fully traceable process. Now, with the input of Imperagen, we can move to even better process intensification and cost-effectiveness”

Dr Ray McCague, head of R&D, Zanoprima Lifesciences

This partnership highlights how digital enzyme engineering is unlocking new levels of performance and sustainability in industrial biocatalysis.